Wellbeing While Waiting: Effectiveness and implementation of youth social prescribing for young people awaiting CAMHS support.

This multisite non-randomised controlled trial demonstrates that social prescribing is a safe and effective adjunct for young people awaiting CAMHS support, significantly improving behavioural difficulties and resilience despite showing no significant impact on anxiety or depression symptoms compared to usual care.

The Gist

Imagine you are waiting for a very important appointment with a specialist doctor, but the wait is incredibly long—maybe eight months or even a year. In the world of mental health, this is exactly what happens when a young person is referred to CAMHS (Child and Adolescent Mental Health Services). They are in distress, they need help, but they are stuck on a waiting list.

For a long time, the advice to families was essentially: "Wait, and try to stay calm." But waiting in limbo often makes things worse. It's like being stuck in a traffic jam with no engine; you aren't moving forward, and the stress of sitting there is burning you out.

This paper, titled "Wellbeing While Waiting," asks a simple question: Can we give these young people something helpful to do while they wait, so they don't fall apart?

The answer they tested is called Social Prescribing.

The Analogy: The "Bridge" vs. The "Detour"

Think of the mental health system as a hospital. The specialist treatment (like therapy) is the operating room. But the waiting list is a long, dark hallway leading to that room.

• Usual Care (The Control Group): These young people were told to just sit in the hallway. They might get a pamphlet or a phone number for a crisis line, but mostly, they just waited.
• Social Prescribing (The Intervention Group): These young people were given a Bridge Builder (called a "Link Worker"). This person didn't try to fix their mental illness directly. Instead, they helped them build a bridge over the hallway, connecting them to the community.

The Link Worker asked the young person: "What makes you feel alive? Do you like art? Football? Volunteering? Do you need help with money for bus tickets?" Then, they connected the young person to local groups, clubs, and activities. They even gave them a small "pocket fund" (up to £40) to help pay for things like a gym pass or art supplies.

What Did They Find?

The researchers tracked 558 young people over six months. Here is what happened, translated into plain English:

1. It Was Safe
First and foremost, this approach didn't hurt anyone. No young person got worse because of the Link Worker. In fact, no "bad side effects" were found at all.

2. The "Symptom" Surprise
The researchers expected to see a massive drop in anxiety and depression scores (the "pain" of the illness). Surprisingly, they didn't. The Social Prescribing group didn't feel significantly less anxious or depressed than the group that just waited.

• Why? Think of it like a broken leg. Social prescribing is like giving you crutches and a map to a park. It helps you move and feel less stuck, but it doesn't instantly knit the bone back together. The "bone" (the clinical anxiety/depression) still needs the specialist doctor (CAMHS) to fix it eventually.

3. The "Function" Win
However, the group with the Link Workers did something amazing: They started functioning better.

• Behavior: They had fewer conduct problems (like fighting or breaking rules).
• Focus: They had less hyperactivity and trouble paying attention.
• Friends: They got along better with peers and were less lonely.
• Resilience: They became tougher. They felt more capable of handling daily challenges.
• Kindness: They actually became more prosocial (helpful and kind to others).

4. The "Happiness" Boost
While their deep anxiety didn't vanish, their day-to-day happiness and sense of "worth" did improve. They felt less like a patient waiting to be fixed and more like a person living a life.

The Big Picture: Why This Matters

This study is like finding a life raft for people stuck in the middle of a storm.

The storm is the long wait for mental health care. The life raft (Social Prescribing) doesn't stop the storm, and it doesn't fix the boat (the underlying mental health condition). But it keeps the person from drowning while they wait for the rescue ship.

The study shows that while Social Prescribing isn't a replacement for professional therapy, it is a powerful tool to:

• Stop young people from sliding further down while they wait.
• Give them a sense of control and choice.
• Help them reconnect with friends and hobbies.
• Build their "muscle" (resilience) so they are stronger when they finally get to see the specialist.

The Takeaway for Everyone

If you or someone you know is stuck waiting for mental health help, this study suggests that getting out of the house and connecting with the community is a valid, safe, and helpful strategy.

It's not about "curing" the problem instantly. It's about keeping the engine running, the wheels turning, and the spirit alive while you wait for the mechanic to arrive. The "Link Workers" in this study were the mechanics who helped the young people change their oil and check their tires so they wouldn't break down completely before the real repair could begin.

Technical Summary

1. Problem Statement

Context:
Child and Adolescent Mental Health Services (CAMHS) in the UK face severe capacity constraints, resulting in median waiting times of nearly eight months for specialist treatment. During these prolonged waits, young people often experience deterioration in mental and physical health, increased distress, and maladaptive coping strategies.

The Gap:
While interim support is critical, evidence-based interventions for young people on waiting lists are limited. Existing reviews show a lack of high-quality, youth-co-designed trials. Social Prescribing (SP)—a non-clinical, community-based approach connecting individuals to activities like arts, sports, and peer support—is increasingly used as a waiting-list intervention. However, there is a significant evidence gap regarding its safety, clinical effectiveness, and implementation feasibility specifically for youth awaiting CAMHS.

2. Methodology

Study Design:

• Type: Multi-site, non-randomised controlled trial embedded within a Hybrid Type II implementation–effectiveness evaluation.
• Design: Pragmatic stepped-wedge design. Due to the staged roll-out of SP across sites, the study compared young people referred to SP (post-implementation) against a control group recruited prior to implementation (usual care/waitlist) at the same 11 sites.
• Setting: 11 CAMHS sites across England with varying demographics and service configurations.
• Timeline: May 2023 – March 2025.

Participants:

• Sample: 558 young people aged 11–18 years referred to CAMHS for short-term psychological intervention.
• Groups:
  • Intervention (SP): 333 participants.
  • Control (Usual Care): 225 participants.
• Exclusion Criteria: Eating disorders, psychosis, or severe/complex mental health difficulties requiring immediate specialist pathways.
• Analytical Sample: 448 participants (after excluding those who did not receive SP and those with missing baseline data).

Intervention (Social Prescribing):

• Mechanism: Young people were assigned a Link Worker (LW) who facilitated a person-centred plan.
• Dose: Typically ~6 sessions (flexible based on need).
• Content: Identification of strengths/goals and connection to community resources (arts, sports, volunteering, etc.).
• Support: Access to a personalized budget (up to £40) to remove financial barriers.
• Control: Usual care involved standard waiting-list management, signposting to self-help, and crisis info, but no structured link-worker support or budget.

Measures & Analysis:

• Primary Outcomes: Anxiety/Depression (RCADS), Total Emotional/Behavioural Difficulties (SDQ), Perceived Stress (PSS).
• Secondary Outcomes: Resilience (SRS), Subjective Wellbeing (ONS items), Prosocial behaviour.
• Implementation Metrics: Reach, dose, acceptability, feasibility, and appropriateness (AIM/FIM/IAM scales).
• Statistical Approach: Growth curve modelling (Stata V18.0) to analyze trajectories across three time points (baseline, 3 months, 6 months), adjusting for age, gender, ethnicity, and socioeconomic status.

3. Key Contributions

• Evidence Generation: Provides the first large-scale, multi-site quantitative evaluation of youth SP specifically as a bridging intervention for CAMHS waiting lists.
• Differentiation of Outcomes: Distinguishes between the effects of SP on symptom reduction (internalising disorders) versus functional improvement (behavioural regulation, resilience, and social participation).
• Implementation Science: Offers real-world data on the feasibility and acceptability of embedding SP within routine CAMHS pathways, including diverse delivery models (embedded vs. external LWs).
• Youth Co-Design: The intervention and outcome measures were developed with a Youth Advisory Group (YAG), ensuring developmental appropriateness.

4. Results

Safety & Implementation:

• Safety: No intervention-related adverse events were observed. 15 adverse events occurred (mostly symptom deterioration), but none were linked to SP.
• Engagement: Of those assigned to SP, 16.2% did not receive it (e.g., lack of consent). Among those who did, the mean dose was 5.05 sessions.
• Acceptability: High acceptability scores from both young people and staff (Mean AIM score: 4.5/5; Feasibility: 4.34/5).

Effectiveness (Primary Outcomes):

• Anxiety & Depression: No significant difference between SP and usual care groups over six months.
• Perceived Stress: No significant difference between groups.
• Total Emotional & Behavioural Difficulties (SDQ): The SP group showed a significant reduction in total difficulties compared to the control group (decrease of 0.15 SD, p=0.006).
  • Drivers: Improvements were driven by reductions in conduct problems, hyperactivity/inattention, and peer problems.
  • Note: No significant difference was found in the "emotional symptoms" domain of the SDQ.
• Prosocial Behaviour: The SP group showed a significant increase in prosocial behaviour, whereas the control group showed a decline.

Effectiveness (Secondary Outcomes):

• Resilience: The SP group demonstrated a significant increase in resilience (0.24 SD increase, p<0.001), particularly in community participation, self-esteem, and problem-solving. The control group showed no change.
• Wellbeing: Both groups improved in life satisfaction and sense of worth. The SP group showed a significant increase in happiness (0.19 SD), though the between-group difference in the rate of change was not statistically significant.

5. Significance and Implications

Clinical Implications:

• Stabilization vs. Cure: The findings suggest SP acts as a stabilizing and protective intervention rather than a direct treatment for internalising symptoms (anxiety/depression). It effectively mitigates the "harm of waiting" by improving day-to-day functioning, behavioural regulation, and social connectedness.
• Target Population: SP is particularly suitable for young people whose difficulties stem from social withdrawal, behavioural dysregulation, and reduced participation, rather than acute internalising pathology.
• Adjunct, Not Substitute: SP should be viewed as a valuable adjunct to clinical care, not a replacement for evidence-based psychological therapies for internalising disorders.

Policy & Systemic Implications:

• Waiting List Management: SP offers a viable, scalable mechanism to address the harms of long waiting lists, providing a "relational bridge" that maintains engagement with services.
• Equity: The study highlights that successful implementation requires addressing structural barriers (transport, costs) and ensuring workforce capacity. Without these, scaling SP risks widening inequalities.
• Future Research: Long-term follow-up is needed to determine if the gains in resilience and functioning eventually translate into reductions in anxiety and depressive symptoms over longer timeframes.

Conclusion:
The "Wellbeing While Waiting" study demonstrates that youth social prescribing is a safe, feasible, and effective intervention for improving behavioural outcomes and resilience in young people awaiting CAMHS. While it does not rapidly reduce anxiety or depression symptoms, it successfully buffers against the deterioration of functioning and social isolation often associated with prolonged waiting periods.